MDT antileprosy drugs: standard regimens from 2010 Anti-leprosy medication A number of<unk> atic agents are available for treatment. A 3-drug regimen of rifampicin, dapsone and clofazimine is recommended for all people with<unk> , for 6 months for paucibacillary<unk>  and 12 months for multibacillary<unk> . Multidrug therapy (MDT) remains highly effective, and people are no longer infectious after the first monthly dose. It is safe and easy to use under field conditions because of its presentation in calendar blister packs. Post-treatment relapse rates remain low. Resistance has been reported in several countries, although the number of cases is small. People with rifampicin-resistant<unk>  may be treated with second line drugs such as fluoroquinolones, minocycline, or clarithromycin, but the treatment duration is 24 months because of their lower bactericidal activity. Evidence on the potential benefits and harms of alternative regimens for drug-resistant<unk>  is not yet available. Skin changes For people with nerve damage, protective footwear may help prevent ulcers and secondary infection. Canvas shoes may be better than PVC boots. There may be no difference between double rocker shoes and below-knee plaster. Topical ketanserin seems to have a better effect on ulcer healing than clioquinol cream or zinc paste, but the evidence for this is weak. Phenytoin applied to the skin improves skin changes to a greater degree when compared to saline dressings.
Leprosy
Sporotrichosis
Onychomycosis
Mumps
Tinea barbae
Tinea faciei
Trichinosis
Tinea manuum